← Back to Search

Other

LY3502970 (Part A) for Healthy Subjects

Phase 1
Waitlist Available
Research Sponsored by Eli Lilly and Company
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up predose up to 92 days postdose
Awards & highlights

Study Summary

This trial tests how well a drug, LY3502970, is absorbed and eliminated in overweight and obese patients and if it's safe and tolerated. It also looks at how food affects it. 135 days total.

Eligible Conditions
  • Healthy Subjects
  • Obesity

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~predose up to 92 days postdose
This trial's timeline: 3 weeks for screening, Varies for treatment, and predose up to 92 days postdose for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
PK: Maximum Observed Concentration (Cmax) of LY3502970
PK: Time to Maximum Observed Concentration (Tmax) of LY3502970
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve from Time Zero to the 24 Hour Time Point (AUC[0-24]) of LY3502970
Secondary outcome measures
PK: AUC[0-24] of LY3502970 in fed state
PK: Cmax of LY3502970 in fed state
PK: Tmax of LY3502970 in fed state

Side effects data

From 2022 Phase 2 trial • 383 Patients • NCT05048719
37%
Nausea
33%
Vomiting
26%
Diarrhoea
22%
Constipation
19%
Eructation
11%
Weight decreased
11%
Flatulence
11%
Dyspepsia
7%
Abdominal distension
7%
Haemoglobin decreased
7%
Decreased appetite
7%
Abdominal pain upper
7%
Retching
7%
Asthenia
7%
Urticaria
4%
Fatigue
4%
Arthralgia
4%
Hypertension
4%
Ischaemic stroke
4%
Lipase increased
4%
Palpitations
100%
80%
60%
40%
20%
0%
Study treatment Arm
36 mg LY3502970 - 1
12 mg LY3502970
24 mg LY3502970
36 mg LY3502970 - 2
45 mg LY3502970 - 1
Placebo
3 mg LY3502970
45 mg LY3502970 - 2
1.5 mg Dulaglutide

Trial Design

2Treatment groups
Experimental Treatment
Group I: LY3502970 (Part B)Experimental Treatment1 Intervention
The multiple doses of LY3502970 administered orally in tablet formulation.
Group II: LY3502970 (Part A)Experimental Treatment1 Intervention
The multiple doses of LY3502970 administered orally either in tablet or capsule formulations.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
LY3502970
2021
Completed Phase 2
~1220

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Eli Lilly and CompanyLead Sponsor
2,613 Previous Clinical Trials
3,200,877 Total Patients Enrolled
Study DirectorEli Lilly and Company
1,344 Previous Clinical Trials
405,200 Total Patients Enrolled

Media Library

LY3502970 (Other) Clinical Trial Eligibility Overview. Trial Name: NCT05841238 — Phase 1
Healthy Subjects Research Study Groups: LY3502970 (Part A), LY3502970 (Part B)
Healthy Subjects Clinical Trial 2023: LY3502970 Highlights & Side Effects. Trial Name: NCT05841238 — Phase 1
LY3502970 (Other) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05841238 — Phase 1
Healthy Subjects Patient Testimony for trial: Trial Name: NCT05841238 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does the experimental program accept individuals below the age of sixty-five?

"According to the eligibility requirements of this trial, individuals between 18 and 70 are considered fit for participation. For those under eighteen or over 65 years old there are 114 studies available while 574 can be found respectively."

Answered by AI

Are there still enrollment opportunities in this research endeavor?

"As evidenced on clinicaltrials.gov, the recruitment phase of this study has concluded; it was initially posted to the website on April 27th 2023 and last updated 24 days later. Although there are no longer any vacancies for this particular trial, 1144 other medical studies have open positions available at present."

Answered by AI

Are there any limitations on who may participate in this experiment?

"To qualify for this research initiative, volunteers must be in good health and between the ages of 18-70. Approximately 50 individuals are needed to fulfill the trial's requirements."

Answered by AI

What safety data is available for LY3502970 (Part A) in clinical trials?

"Due to the minimal amount of information available on LY3502970 (Part A), our team at Power have given it a safety rating of 1. This is because this trial is only in Phase 1, thus there are limited results regarding its efficacy and safety profile."

Answered by AI

Who else is applying?

What state do they live in?
Kansas
Wisconsin
Other
Texas
What site did they apply to?
LabCorp CRU, Inc.
Labcorp Clinical Research LP
What portion of applicants met pre-screening criteria?
Met criteria
How many prior treatments have patients received?
0
1
3+

Why did patients apply to this trial?

I'm trying to find a viable long-term solution for achieving my weight loss goals.
PatientReceived 2+ prior treatments
Recent research and studies
clinicaltrials.govStudy
A Multiple Dose Study of LY3502970 in Healthy Overweight and Obese Participants
2023. "A Multiple Dose Study of LY3502970 in Healthy Overweight and Obese Participants". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05841238.
~27 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top